CDER Free Speech Response Complicated By Family Ties
This article was originally published in RPM Report
Executive Summary
It’s hard enough for FDA to try to chart its course on promotional claims in the face of shifting opinions in the courts. Now, the CDER management team has to deal with a change in leadership of one of the key internal groups monitoring the issue.
You may also be interested in...
FDA Taps NIH Veteran Corrigan-Curay To Lead Medical Policy Office
Jacqueline Corrigan-Curay joins from the National Heart, Lung and Blood Institute, where she worked on clinical trial initiatives and served as an NIH representative on FDA’s Drug Safety Oversight Board.
US Price Negotiation Hearing Lays The Groundwork For Future Improvements
The pharma industry is hoping that litigation might end Medicare price negotiation before it begins. But a House hearing also starts the process of developing legislative improvements that might be viable in years to come – starting with trying to restore the lifespan of small molecules.
As Sickle Cell Gene Therapies Move To Market, Health Inequities Could Help Pricing Debate
Positive tandem ICER reviews for bluebird bio’s and Vertex/CRISPR’s gene therapies show the impact that concerns about addressing racial inequities could create a favorable context for products as they enter pricing and coverage discussions.